[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified
Analysis of the ALIENTO and ARNASA data will be discussed with regulatory authorities and shared at an upcoming medical meeting
Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.
The pivotal phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualised exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given every two weeks. However, the phase III ARNASA study did not meet its primary endpoint of a statistically significant reduction in the AER, demonstrating a numerical 14.5% reduction, at 52 weeks when astegolimab was given every two weeks. The results were generally consistent across secondary endpoints in both studies. The total number of exacerbations was lower than prospectively anticipated in both trials. The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified.
"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for managing this debilitating and complex disease," said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. "This was the first set of studies in an 'all-comers' COPD population, and we will discuss these data with regulatory authorities to evaluate next steps for astegolimab.'
Detailed results from ALIENTO and ARNASA will be shared at an upcoming medical meeting.
About the ALIENTO and ARNASA studies1,2Astegolimab is an investigational, fully human anti-ST2 monoclonal antibody designed to bind with high affinity to the ST2 receptor, thereby blocking the signalling of IL-33.3 The astegolimab COPD pivotal programme consists of two registrational studies, the phase IIb ALIENTO (NCT05037929) and phase III ARNASA (NCT05595642) studies. Both ALIENTO and ARNASA are double-blinded, placebo-controlled, multicentre studies that evaluate the efficacy and safety of astegolimab administered every two or every four weeks in patients with COPD on top of standard of care maintenance therapy. Patients in the studies included former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The primary analysis is based on the initial phase of the study, which consisted of 1,301 patients for ALIENTO and 1,375 patients for ARNASA. The primary endpoint is the reduction in the annualised rate of moderate and severe COPD exacerbations (AER) over the 52-week treatment period. AER is the total number of exacerbations (a sudden worsening in airway function and respiratory symptoms) occurring over the relevant treatment period, divided by the total number of patient years. Standard of care maintenance therapy for both studies was one of the following combinations – inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA); long-acting muscarinic antagonist (LAMA) plus LABA; ICS plus LAMA plus LABA.
About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.References[1] A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA). [Internet; cited March 2025]. Available from: https://clinicaltrials.gov/study/NCT05595642. [2] A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease. [Internet; cited March 2025]. Available from: https://clinicaltrials.gov/study/NCT05037929.[3] Kelsen SG, Agache O, Soong W, Israel E, Chupp GL, Cheung DS, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. Journal of Allergy and Clinical Immunology. 2021 Sep;148(3):790–8.
Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhDPhone: +41 79 407 72 58
Sileia UrechPhone: +41 79 935 81 48
Nathalie AltermattPhone: +41 79 771 05 25
Lorena CorfasPhone: +41 79 568 24 95
Simon GoldsboroughPhone: +44 797 32 72 915
Karsten KleinePhone: +41 79 461 86 83
Kirti PandeyPhone: +49 172 6367262
Yvette PetillonPhone: +41 79 961 92 50
Dr Rebekka SchnellPhone: +41 79 205 27 03
Roche Investor Relations
Dr Bruno EschliPhone: +41 61 68-75284e-mail: bruno.eschli@roche.com
Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: sabine.borngraeber@roche.com
Dr Birgit MasjostPhone: +41 61 68-84814e-mail: birgit.masjost@roche.comInvestor Relations North America
Loren KalmPhone: +1 650 225 3217e-mail: kalm.loren@gene.comAttachment
Media Investor Release Astegolimab ALIENTO ARNASA English
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
4 hours ago
- Yahoo
Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75
Sir David Nabarro, who was the World Health Organisation's (WHO) special envoy for Covid-19, has died aged 75. The WHO's director-general Dr Tedros Adhanom Ghebreyesus said he was 'deeply shocked and saddened by the passing' of Sir David. London-born Sir David worked at the United Nations for 17 years, expanding nutrition programmes to underdeveloped countries and tackling health crises including outbreaks of malaria, bird flu and Ebola, before leaving in 2017. He was appointed as special envoy on Covid-19 for the WHO in 2020 and appeared on news programmes regularly throughout the pandemic, telling Sky News in June 2021 that humanity was going to have to learn how to 'co-exist' with Covid-19. Sir David was knighted at Buckingham Palace in March 2023 for his outstanding contribution to global health. Dr Tedros wrote on X: 'Deeply shocked and saddened by the passing of our dear friend, colleague and WHO Envoy David Nabarro. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals. 'His work touched and impacted so many lives across the world. 'On behalf of WHO, I'm extending our heartfelt condolences to David's family, friends and colleagues. 'Rest in peace, my dear friend. We will dearly miss your expertise, wisdom and kindness.'
Yahoo
4 hours ago
- Yahoo
Best-ever map of the human genome sheds light on 'jumping genes,' 'junk DNA' and more
When you buy through links on our articles, Future and its syndication partners may earn a commission. Twenty-two years after the completion of the Human Genome Project, scientists have unveiled the most expansive catalog of human genetic variation ever compiled. Across two new papers published Wednesday (July 23) in the journal Nature, scientists sequenced the DNA of 1,084 people around the world. They leveraged recent technological advancements to analyze long stretches of genetic material from each person, stitched those fragments together and compared the resulting genomes in fine detail. The results deepen our understanding of "structural variants" within the human genome. Rather than affecting a single "letter" in DNA's code, such variations affect large chunks of the code — they may be deleted from or added to the genome, or encompass places where the DNA has been flipped around or moved to a different location. The studies have revealed "hidden" features of the human genome that were previously too technologically challenging to study, said Jan Korbel, the interim head of European Molecular Biology Laboratory (EMBL) Heidelberg, who is a co-author of both new papers. For instance, large portions of the genome contain codes that repeat over and over, and these were thought to be nonfunctional. "Some 20 years ago, we thought about this as 'junk DNA' — we gave it a very bad term," Korbel told Live Science. "There's more and more the realization that these sequences are not junk," and the new work sheds light on these long-maligned DNA sequences. Additionally, all of the data generated in the new studies are open access, so others in the field can now take "the findings, some of the tools we've developed and use them for their purposes to understand the genetic basis of disease," Korbel told Live Science. "I thoroughly believe that the advances that we're publishing in Nature today, a subset of these will also make it into diagnostics." Related: People's racial and ethnic identities don't reflect their genetic ancestry Over 1,000 genomes When the first draft of a "complete" human genome was published in 2003, it was actually missing about 15% of its sequence due to technological limitations of the time. In 2013, scientists managed to close that gap by about half. And finally, in 2022, the first "gapless" human genome was published. In 2023, researchers published the first draft of a human pangenome, which incorporated DNA from 47 people around the world, rather than predominantly being based on one person's DNA. And that same year, researchers published the first Y chromosome that had ever been sequenced from end to end, because the previous "gapless" genome was still missing the male sex chromosome. In the past few years, the field has continued to advance, thanks to new technologies and efforts to expand DNA sampling beyond populations of mostly European descent. Those advancements heralded the two papers published in Nature this week. In the first study, researchers sequenced the DNA of 1,019 people representing 26 populations across five continents. To analyze the DNA, the researchers collected "long reads," each composed of tens of thousands of base pairs; one base pair corresponds with one rung in the spiral ladder of a DNA molecule. "With short reads of around 100 base pairs, it is difficult to distinguish between genomic regions that look alike," explained study co-author Jesus Emiliano Sotelo-Fonseca, a doctoral student at the Centre for Genomic Regulation (CGR) in Barcelona, Spain. That's especially true in repetitive regions of the genome. "With longer reads, of around 20k base pairs, assigning each read to a unique position in the genome gets much easier," he told Live Science in an email. More than half of the new genomic variation uncovered in the study was found in those tricky repetitive regions, including in transposons, also known as jumping genes. Transposons can leap to different locations in the genome, copying and pasting their code. Sometimes, depending on where they land, they can destabilize the genome, introduce harmful mutations and contribute to diseases like cancer. "Our study reveals that some of these transposons can hijack regulatory sequences to boost their activity, contributing to understanding the biological mechanisms behind their mutagenicity," or ability to trigger mutations, study co-author Bernardo Rodríguez-Martín, an independent fellow at CGR and a former postdoc in Korbel's EMBL lab, told Live Science in an email. The jumping genes can essentially hitch a ride with certain regulatory molecules — long noncoding RNAs — and use that trick to make far more copies of themselves than they usually would. "That's a very surprising mechanism to us," Korbel said. Related: Scientists just discovered a new way cells control their genes From 95% to 99% The second study featured far fewer genomes — only 65 in total — but sequenced those genomes more comprehensively than the first study did. The first study captured about 95% of each genome analyzed, while the second study generated 99%-complete genomes. "It might sound like a small difference, but it's huge actually from the perspective of the genome scientist," Korbel said. "To get the last few percentages, it's a major achievement." That leap required different sequencing techniques, as well as new analytical approaches. "This project used cutting-edge software to assemble genomes and identify genetic variation, much of which simply did not exist a few years ago," co-author Charles Lee, a professor at the Jackson Laboratory for Genomic Medicine, told Live Science in an email. The sequencing techniques included one that generated long reads with very few errors and one that generated ultralong reads that were slightly more error-prone. At the expense of analyzing fewer genomes, this approach nonetheless enabled the second study to capture stretches of DNA that were totally missed in the first, Rodríguez-Martín said. Those "hidden" regions included the centromeres, important structures at the centers of chromosomes that are key for cell division. As a cell prepares to split, fibers attach to the centromeres and then pull the chromosome in two. The study found that, in about 7% of centromeres, there are likely two places where these fibers can attach, instead of only one. "Could that mean that those chromosomes are more unstable? Because if the spindle [fiber] attaches to two points, it might get confused," Korbel said. That's a purely speculative idea, he added, but it's one that can now be explored. The next step will be to study the effects of these centromere variations experimentally, Lee agreed. Issues with chromosome splitting can lead to various conditions. For example, "Down syndrome is the result of a mistake of chromosome segregation during cell division in meiosis," when cells split to form sperm and eggs, co-author Dr. Miriam Konkel, an assistant professor at the Clemson University Center for Human Genetics, told Live Science in an email. Like the first study, the second study also provided an unprecedented look at jumping genes, cataloging more than 12,900. Beyond cancer, jumping genes can also trigger various genetic diseases by causing mutations, as well as prompt more subtle changes in how genes are switched on and off, Konkel noted. A better understanding of the diversity of jumping genes can help unpack their function in human health and disease. Looking at both studies, scientists can now compare the newly sequenced genomes to other datasets that include both genome and health data, Korbel noted. This would be the first step toward linking the newfound structural variations to tangible health outcomes and, eventually, to incorporating those insights into medical practice. RELATED STORIES —Largest human family tree ever created retraces the history of our species —More than 150 'made-from-scratch' genes are in the human genome. 2 are totally unique to us. —As little as 1.5% of our genome is 'uniquely human' "Certain clinical studies will not be able to ignore these [sequencing] techniques because they will give them higher sensitivity to identify variation," Korbel said. "You don't want to miss variants." There's still more work to be done to improve the genomic data, as well, Lee added. More DNA could be incorporated from underrepresented populations, and the sequencing techniques and software could be further refined to make the process more efficient and accurate. But in the meantime, the pair of new studies marks a major technological feat. "These advanced tools were developed recently to handle the huge amounts of long-read data we are now using for each genome," Lee said. "A few years back, assembling a complete human chromosome from end to end, especially including centromeres, was virtually unattainable because the software and algorithms were not mature yet." Solve the daily Crossword
